Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.
暂无分享，去创建一个
J. Hengstler | W. Uhl | A. Tannapfel | A. Maghnouj | S. Hahn | R. Viebahn | H. Wolters | C. Schultz-Fademrecht | M. Trajkovic-Arsic | J. Siveke | D. Rauh | M. Baumann | Georgia Günther | J. Weisner | M. Pohl | Anke Unger | C. Teschendorf | M. Müller | S. Ladigan | Steven Smith | Heiko Müller | I. Landel | Christoph Reintjes | Niklas Uhlenbrock | N. Dienstbier | J. Hardick | Marius Lindemann | Lena Quambusch | R. Scheinpflug | L. Depta | Rajesh Gontla | Carsten Schultz-Fademrecht | R. Gontla | Niklas Dienstbier